Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
P
P

Pfizer


Balita

Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial

UPDATE 1-Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial Adds background on data and disorder throughout July 24 (Reuters) - Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment, the company said on Wednesday.
B
P

Pfizer Announces Positive Topline Results From Phase 3 Study Of Hemophilia A Gene Therapy Candidate

BRIEF-Pfizer Announces Positive Topline Results From Phase 3 Study Of Hemophilia A Gene Therapy Candidate July 24 (Reuters) - Pfizer Inc PFE.N : PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF HEMOPHILIA A GENE THERAPY CANDIDATE PFIZER: ANALYSES OF FULL PHASE 3 DATASET FROM AFFINE STUDY ONGOING PFIZER: IN AFFINE STUDY, GIROCTOCOGENE
P

Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial

Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial July 24 (Reuters) - Pfizer PFE.N said on Wednesday that its gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment.
P

Merck's RSV shot helps protect infants in mid-to-late stage study

UPDATE 3-Merck's RSV shot helps protect infants in mid-to-late stage study Adds analyst comment in paragraph 3 By Vaibhav Sadhamta July 23 (Reuters) - Merck's MRK.N antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV), the company said on Tuesday.
A
P
S

GSK's Viiv Healthcare Announces Positive New Data For Apretude Use During Pregnancy

BRIEF-GSK's Viiv Healthcare Announces Positive New Data For Apretude Use During Pregnancy July 23 (Reuters) - GSK plc GSK.L : GSK: VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DATA FOR APRETUDE USE DURING PREGNANCY GSK: VIV'S FINDINGS SHOW MATERNAL AND PREGNANCY OUTCOMES WITH APRETUDE EXPOSURE WERE COMPARABLE TO THOSE WITH NO CABOTEGRAVIR EXPOSURE Source
G
P

Collaboration software maker Smartsheet fields buyout interest, sources say

EXCLUSIVE-Collaboration software maker Smartsheet fields buyout interest, sources say Adds share reaction in paragraph 4 By Milana Vinn and Anirban Sen July 18 (Reuters) - Smartsheet SMAR.N , a U.S. maker of workplace collaboration software with a market value of $6.6 billion, has tapped investment bankers after attracting acquisition interest from buyout firms, according to people familiar with the matter.
C
P

Collaboration software maker Smartsheet fields buyout interest, sources say

EXCLUSIVE-Collaboration software maker Smartsheet fields buyout interest, sources say By Milana Vinn and Anirban Sen July 18 (Reuters) - Smartsheet SMAR.N , a U.S. maker of workplace collaboration software with a market value of $6.3 billion, has tapped investment bankers after attracting acquisition interest from buyout firms, according to people familiar with the matter.
C
P

Novo Nordisk obesity feast no longer a free lunch

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, July 18 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO is going to have to work hard to justify its bulging valuation. The $603 billion obesity drug maker’s shares have more than trebled since 2021 thanks to insatiable appetite for its weight-loss drug.
A
P
R
I

Valneva Says Co And Pfizer Announce Primary Vaccination Series Completion

BRIEF-Valneva Says Co And Pfizer Announce Primary Vaccination Series Completion July 17 (Reuters) - Valneva SE VLS.PA : PHASE 3 VALOR LYME DISEASE TRIAL: VALNEVA AND PFIZER ANNOUNCE PRIMARY VACCINATION SERIES COMPLETION VALNEVA - PRIMARY VACCINATION SERIES TO BE FOLLOWED BY A BOOSTER APPROXIMATELY ONE YEAR AFTER COMPLETION VALNEVA SE: PFIZER PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) TO U.S.
P

Mark Cuban's Cost Plus to import penicillin to address US shortage (July 17)

CORRECTED-Mark Cuban's Cost Plus to import penicillin to address US shortage (July 17) Removes reference in July 17 story to Pfizer's pediatric version of Bicillin-L-A in paragraph 3 July 17 (Reuters) - Mark Cuban's Cost Plus Drug Company said on Wednesday that it is working with the U.S. Food and Drug Administration to import and distribute penicillin in the country temporarily.
P

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates with latest details on Pfizer, Roche and Carmot Therapeutics July 17 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.
A
O
P
R

Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason

Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason JERUSALEM, July 17 (Reuters) - Israel's CytoReason, which uses AI to develop disease models, said on Wednesday it had raised $80 million in a private funding round. Nvidia NVDA.O , Pfizer PFE.N , Thermo Fisher TMO.N and venture capital investor OurCrowd participated in the round, CytoReason said.
N
P
T

EU court criticises Commission over handling of COVID vaccine contracts

UPDATE 3-EU court criticises Commission over handling of COVID vaccine contracts Adds more reaction from Commission in paragraphs 8-10 By Foo Yun Chee and Bart H. Meijer BRUSSELS, July 17 (Reuters) - Europe's second-highest court on Wednesday criticised the European Commission for a lack of transparency over COVID-19 vaccine contracts four years ago, a day before a key vote on Commission head Ursula von der Leyen's bid for a second term.
A
P
S

Roche touts early trial success of second obesity drug candidate

UPDATE 4-Roche touts early trial success of second obesity drug candidate Adds executive comment from paragraph 11 By Ludwig Burger and Paolo Laudani July 17 (Reuters) - Roche ROG.S said on Wednesday a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs.
P
R

U.S. STOCKS Pure Cycle, Tesla, Five9

BUZZ-U.S. STOCKS ON THE MOVE-Pure Cycle, Tesla, Five9 Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 fell from record highs on Thursday, weighed by megacap stocks, as investors favored small-caps after a softer-than-expected inflation reading bolstered hopes that the U.S.
A
A
B
C
C
C
F
I
P
P
P
T
V
D
W
U
U
E

U.S. STOCKS Delta Air Lines, Crypto stocks, Solar stocks

BUZZ-U.S. STOCKS ON THE MOVE-Delta Air Lines, Crypto stocks, Solar stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes struggled for direction on Thursday as investors favored rate-sensitive small-cap stocks over expensive megacaps after a softer-than-expected inflation reading bolstered hopes for monetary policy easing in September.
A
B
C
C
F
N
P
P
P
V
L
A
W
U
U
I
M
R

U.S. STOCKS Alcoa, 40, Broadcom

BUZZ-U.S. STOCKS ON THE MOVE-Alcoa, WD-40, Broadcom Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street futures turned positive on Thursday after data showed inflation eased in June, boosting expectations of
A
B
C
C
P
P
P
V
L
W
U
R

Wall Street set for stronger open after inflation print; airlines slump on Delta forecast

US STOCKS-Wall Street set for stronger open after inflation print; airlines slump on Delta forecast CPI data shows inflation eased in June PepsiCo dips on quarterly revenue miss Pfizer moves ahead with once-daily weight-loss pill, shares up Futures up: Dow 0.17%, S&P 500 0.22%, Nasdaq 0.28% Updated at 8:42 a.m. ET/1242 GMT By Lisa Pauline Mattackal and Ankika Biswas July 11 (Reuters) - Wall Street futures turned positive on Thursday after data showed inflation eased in June, boosting expectation
A
J
N
P
P
A
U
U
U
U
A

Pfizer's move to press ahead with weight-loss pill drags some drug developers

BUZZ-Pfizer's move to press ahead with weight-loss pill drags some drug developers Updates ** Shares of weight-loss drug developer Viking Therapeutics VKTX.O fall ~4.3% to $55.50 premarket ** Pfizer PFE.N plans to advance a reworked, once-a-day version of its experimental obesity pill, danuglipron, to clinical trials in the second half of this year
P

U.S. STOCKS Costco, PepsiCo, Alcoa

BUZZ-U.S. STOCKS ON THE MOVE-Costco, PepsiCo, Alcoa Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. index futures slipped on Thursday on expectations that a key inflation print could shaperate-cuts bets and put Wall Street's record-breaking run to the test, while Delta Air Lines slumpedafter a weak forecast, dragging other airline stocks.
A
C
C
P
P
P
V
L
W
U



Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.